We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Animalcare Group Plc | LSE:ANCR | London | Ordinary Share | GB0032350695 | ORD 20P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 4.00 | 1.44% | 282.00 | 73,640 | 12:41:52 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 276.00 | 288.00 | 282.00 | 278.00 | 278.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Veterinary Service-livestock | 74.84M | 18.49M | 0.2681 | 10.52 | 191.79M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:43:58 | O | 20,000 | 282.717 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 13/6/2025 | 10:57 | ALNC |  Animalcare shares down as it invests GBP1.4 million in Australia |
| 13/6/2025 | 07:42 | UK RNS | Animalcare Group PLC Strategic investment in Australian business |
| 10/6/2025 | 16:36 | UK RNS | Animalcare Group PLC Result of 2025 AGM |
| 30/5/2025 | 07:00 | UK RNS | Animalcare Group PLC Exercise of Options and Total Voting Rights |
| 23/5/2025 | 09:21 | UK RNS | Animalcare Group PLC Notification of Major Holding in Company |
| 16/5/2025 | 07:00 | UK RNS | Animalcare Group PLC 2024 Annual Report and Notice of 2025 AGM |
| 29/4/2025 | 21:02 | ALNC | EARNINGS: Animalcare sees profit growth; Star Energy swings to loss |
| 29/4/2025 | 14:06 | UK RNS | Animalcare Group PLC Final Dividend Timetable |
| 29/4/2025 | 07:00 | UK RNS | Animalcare Group PLC Preliminary Full Year Results |
| 22/4/2025 | 13:23 | UK RNS | Animalcare Group PLC Notification of Major Holding in Company |
Animalcare (ANCR) Share Charts1 Year Animalcare Chart |
|
1 Month Animalcare Chart |
Intraday Animalcare Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 29/5/2025 | 18:19 | Animalcare : contrarian value opportunity ? | 241 |
| 06/3/2019 | 20:37 | ANIMALCARE GROUP/Ritchey | 132 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 15:43:59 | 282.72 | 20,000 | 56,543.40 | O |
| 15:41:59 | 282.80 | 8,174 | 23,116.07 | O |
| 15:25:48 | 279.82 | 437 | 1,222.81 | O |
| 15:13:34 | 283.50 | 24,045 | 68,167.58 | O |
| 13:10:33 | 279.44 | 3,950 | 11,037.88 | O |
| Top Posts |
|---|
Posted at 16/6/2025 09:20 by Animalcare Daily Update Animalcare Group Plc is listed in the Veterinary Service-livestock sector of the London Stock Exchange with ticker ANCR. The last closing price for Animalcare was 278p.Animalcare currently has 68,989,072 shares in issue. The market capitalisation of Animalcare is £194,549,183. Animalcare has a price to earnings ratio (PE ratio) of 10.52. This morning ANCR shares opened at 278p |
Posted at 27/5/2025 15:05 by p1nkfish Interesting price action. I own a lot of these and put a dummy sell at volume at much higher than the average daily volume of the past 3 months to add to what has already gone through today. Didn't expect to get a price but no problem getting full ask. I didn't execute. Someone wants in. Is some news due or is it just blind buying? |
Posted at 18/5/2025 09:25 by p1nkfish Adam, difference between the pbtax and pat is due to non-underlying items (that make it harder to understand the core business performance), particularly the gains from their disposals and the amortization and impairment charges. Not so much minority interests or tax expenses.In 2024 there was profit on sale of holding in STEM and bigger gain on sale of Indenticare. About £17M? They impaired and amortized intangibles related to acquisition of about £2M. Total about £15M all in just for those 2. Best days for ANCR are ahead but patience needed. |
Posted at 30/4/2025 07:46 by simon gordon FT last week:US vet visits are down. A recession omen, or is price gouging to blame? Dissecting a dead-cat indicator It’d be nice to imagine that veterinary services are recession-proof. Worming tablets and hairball treatments seem like they should be non-discretionary purchases. The $60bn-plus of private equity cash flowing into petcare over the past decade was premised on the hope that demand would be price-inelastic. A Morgan Stanley/AlphaWise survey of 75 US vet practices showed first-quarter patient volumes dropping 1.9 per cent in the first quarter, the worst reading since the series began in mid-2021. Vet practice revenue showed its first decline on record, down 0.5 per cent, the survey showed, with more than three-quarters of vets saying that customers have been arguing about prices. They reported declines in new patient appointments, existing patient check-ups, diagnostic testing and discretionary procedure volumes. Morgan Stanley’s survey finds that of all vet services offered, acute care was the only category from which revenues continued to tick higher. A decline in preventive treatment probably helped that trend. If pushback on vet bill inflation continues to strengthen and the US economic outlook continues to weaken, that’s probably not good for the life expectancies of Milo and Luna. |
Posted at 29/4/2025 21:02 by simon gordon Perplexity:Key Negatives in Animalcare plc's Preliminary Full Year Results Announcement While Animalcare plc’s 2024 results highlight solid revenue growth, strategic acquisitions, and strong cash generation, several negatives and areas of concern are evident in the announcement. 1. Decline in Gross Margin Gross margins decreased from 56.8% in 2023 to 55.6% in 2024, attributed to input cost inflation and unfavorable exchange rates. This margin compression, despite positive sales mix, indicates cost pressures that could persist or worsen if inflation remains high or FX volatility continues. 2. Flat Underlying EBITDA and Operating Profit Underlying EBITDA was essentially flat year-on-year (£11.6m in 2024 vs £11.6m in 2023), and underlying operating profit actually declined by 3.3%. This suggests that while revenues grew, profitability did not improve, reflecting increased costs, particularly in people and marketing, and possibly reduced operational leverage. 3. Increased Net Debt Post-Acquisition Net debt rose significantly to £9.0m at year-end 2024 (excluding lease liabilities), up from £1.2m in 2023, primarily due to the acquisition of Randlab. While leverage remains below 2x EBITDA (the company’s target), the higher debt load reduces financial flexibility, especially if integration challenges or unforeseen headwinds emerge. 4. Heavy Reliance on Disposals and Equity Raise The funding for the Randlab acquisition was supported by the disposal of Identicare and STEM, as well as an equity raise. This reliance on asset sales and new equity could be a warning sign if future growth depends on similar transactions rather than organic cash flow. 5. Ongoing Cost and Investment Pressures The company continues to invest heavily in people and marketing, which, while necessary for growth, has so far not translated into increased EBITDA or operating profit. If these investments do not yield expected returns, profitability could suffer further. 6. Integration and Execution Risks The Randlab acquisition is described as “transformatio 7. Dividend Cover and Payout Sustainability The proposed full-year dividend remains at 5.0p per share, but with flat underlying earnings per share (10.9p), the dividend cover is just over 2x. If profitability stagnates or declines, dividend sustainability could come under pressure. 8. Market and Currency Headwinds The report acknowledges ongoing risks from input inflation and currency movements, both of which impacted 2024 results and could continue to do so. 9. Share Price Underperformance The company’s share price fell 13% in the three months leading up to the announcement, suggesting investor concerns about growth, profitability, or the risks associated with recent strategic moves. Conclusion Animalcare’s 2024 announcement is positive on the surface, but the negatives-margin pressure, flat profits, increased debt, reliance on disposals and equity raises, and integration risks-suggest that the company’s growth strategy carries significant financial and operational risks. Investors should monitor the impact of the Randlab integration, the company’s ability to convert revenue growth into profit, and any further erosion in margins or cash flow. ----- Perplexity: Key Positives in Animalcare plc's 2024 Preliminary Full Year Results 1. Solid Revenue Growth Across All Product Categories Animalcare delivered a 4.9% increase in revenues from continuing operations (7.2% at constant exchange rates) to £74.2 million, with growth achieved in all three product categories: Companion Animals, Production Animals, and Equine. This demonstrates broad-based demand and operational effectiveness. 2. Significant Profit Improvement Reported profit before tax rose sharply to £5.8 million from £3.3 million in 2023, indicating improved profitability despite margin pressures. Underlying continuing earnings per share also increased by 10.1% to 10.9 pence. 3. Transformational Acquisition of Randlab The post-year-end acquisition of Randlab, a leading Australian equine veterinary business, is described as transformational. This deal strengthens Animalcare’s position in the equine sector and provides access to Asia Pacific markets, supporting future growth and international expansion. The acquisition is expected to be materially earnings accretive by at least 20% in financial 2025. 4. Strong Cash Generation and Balance Sheet Flexibility The disposal of non-core assets (Identicare and STEM) brought in significant cash, enhancing the company’s financial position and providing “firepowerR 5. Strategic Progress and Investment in Growth Animalcare continued targeted investment in people and marketing, supporting future growth and operational capability. The company also added three new development projects to its pipeline, each with potential for over £10 million in value, and achieved positive early clinical data for a potentially game-changing product. 6. Outperformance of Key Growth Brands Flagship products like Daxocox and Plaqtiv+ delivered strong double-digit growth (30–50%), offsetting declines in more mature parts of the portfolio and underlining the success of recent product launches. 7. Enhanced Product Pipeline and Innovation Focus The company’s development pipeline is robust, with new projects and a focus on differentiated products, especially in biologics. Animalcare is committed to increasing investment in its pipeline, aiming for long-term growth through innovation. 8. Successful Execution of Non-Core Asset Disposals The sale of Identicare at approximately 17x EBITDA and exit from the STEM JV at around 2x the original investment delivered strong returns, demonstrating effective capital allocation and portfolio management. Conclusion Animalcare’s 2024 results highlight a year of strategic progress, operational delivery, and strengthened foundations for future growth, positioning the company well for continued expansion and innovation. ----- Perplexity: Animalcare’s forward price/earnings (P/E) ratio for 2025 is around 17x. To assess whether this is expensive or cheap, it’s helpful to compare it with both industry peers and broader market averages: Peers and Sector Comparison: Pets at Home, a UK-listed pet care company, has a forward P/E of 10.7x, with a ten-year average of 15.6x. Phibro Animal Health (PAHC), a US animal health peer, has a forward P/E that fluctuates widely but its median over the past 13 years is about 18.5x, and currently trades at 10.99x (without non-recurring items). Zoetis, a global animal health leader, has a forward P/E of 24.7x. Elanco Animal Health trades at a trailing P/E of about 14x. Animalcare’s Position: Animalcare’s forward P/E of 17x is slightly above the sector’s lower end (Pets at Home, Elanco), below the global leader Zoetis, and close to the long-term median for the sector. It is also in line with its own historical range, with recent data showing a forward P/E between 14.9x and 17x. Conclusion Animalcare’s forward P/E of 17x is neither particularly expensive nor especially cheap. It sits around the sector average and is reasonable relative to peers and historical norms. The valuation reflects moderate growth expectations and the company’s solid fundamentals, but does not offer a clear discount compared to similar companies in the animal health sector. |
Posted at 13/4/2025 07:01 by simon gordon Hugh Sergeant - 12/4/25Why this is a generational opportunity to buy UK Equities and smaller companies in particular: 1) They are cheap. The UK market is on 11x not very buoyant earnings, and smaller companies are on less than 10x quite depressed profits. 2) Money's Coming Home (it's coming home....) The risk premium on US stocks, exceptionally low for some time now is going up because of Trump and deficits. The USD is under pressure. All those UK based investing institutions and their gatekeepers who have argued that the 4% global benchmark weighting is the right allocation for UK investors in their domestic market will have to change tack...just imagine what will happen to small company share prices if they actually have buyers! 2) Rachel Reeves favourite word is GROWTH, because she realises this is the one answer to all her problems. The Government's economic policies are now recognising this, and Trump has provided a perfect smokescreen for a shift to growth and market friendly policies and of course loving free trade. 3) The Government's least favourite word is NO, followed closely by Inquiry. So anti growth regulators, civil servants, planners who say NO, and endless expensive inquiries are out. This will help deliver on 2. 4) Self help abounds. From Make UK Equities Great Again, to Mansion House Reforms, to the GB ISA or Wealth Fund, to relaxing listing rules, to encouraging our great Fintechs to be the cheerleaders for the UK market, to companies buying in huge quantities of stock, all the players in the UK market are practicing self help. |
Posted at 29/3/2025 11:47 by simon gordon Innovation, innovation, innovation. ANCR's ProAuris is the first live probiotic ear drop for animals. Mentioned it to my vet yesterday, as my dog is going to have a Fecal Transplant. One of the vet's in practice is going to take some stool from his dog and the practice will have it screened under two tests. If the donor is sound, my dog will go to the practice for the day, and the other dog will be there as well, and when it drops one, they will take some of the stool and prepare it, put my dog under and give him an enema. I'm hoping this will help his inflammatory bowel / dysbiotic gut issue. Vet has tried him on many drugs, one drug had his hair falling out. He currently eats Kangaroo mince and Sweet Potato, the Kangaroo is the most novel protein I can source. He's just about eaten everything else: Horse, Rabbit, Insect, Vegan, etc.Future looks bright for ANCR. Wonder if they can get Daxocox and Plaqtiv into China. |
Posted at 28/3/2025 14:38 by simon gordon Is ANCR being caught up in IHT selling, as mentioned in this piece on how it's affected AMS:Proactive Investor - 28/3/25 Advanced Medical Solutions: Beware the lowball offer, broker warns Panmure Liberum has urged shareholders of Advanced Medical Solutions Group (AIM:AMS) to hold firm and reject any takeover bid that doesn’t come in above 300p a share, following confirmation late Thursday that Montagu Private Equity has made an approach. While no formal offer has been tabled, the fact that interest from Montagu is now public adds weight to the long-running takeover chatter around AMS, a specialist in wound care products and surgical dressings. Panmure warns that any deal now risks undervaluing the business, particularly with the share price still recovering from the knock-on effects of recent changes to inheritance tax rules. The broker believes private equity could exploit this temporary weakness to pick up AMS on the cheap — an outcome that would benefit buyers, not long-term investors. “This clearly isn’t what the Chancellor had in mind,” Panmure said, referring to the potential side effects of the tax changes, “but it may be the unintended consequence.” |
Posted at 04/3/2025 20:19 by simon gordon Times - 4/3/25:London markets need a dose of optimism to keep them attractive No one is a bigger supporter of London’s capital markets than me. There are excellent people running finance companies and leading businesses in London. When our chairman, Andrew Brode, and I listed Learning Technologies Group (LTG) on the London Stock Exchange in 2013 we believed it was the best way to raise money to make deals. Last week, however, we both voted in favour of a takeover by the US private equity firm General Atlantic. LTG’s independent board came to the same conclusion. As a private company we will be better equipped to handle the challenges and opportunities that artificial intelligence presents with the backing of a private equity firm that understands how to help technology businesses to grow. So what does this say about the state of London’s markets? The Aim market gave LTG an exceptional platform in our first eight years as a listed company. We made 17 acquisitions to become the leading consolidator in the learning and talent development industry. This supported LTG’s growth from a hundred people and £10 million revenues in 2013 to more than five thousand people and nearly £500 million revenues today. The fact is, though, for the past three years the markets simply did not serve their purpose of raising money and valuing businesses fairly. The increasingly challenging macroeconomic backdrop has not been kind to the markets and LTG. Despite doubling profit in 2022 we lost a quarter of our value after a minor, technical balance sheet restatement. I reflected long and hard on London’s capital markets before deciding to leave. One of my conclusions is that investors disproportionately punish negative news but do not reward positive news. For instance, our share price reduced significantly because we had debt on our balance sheet as interest rates rose. By 2024 we eliminated our debt but our share price did not recover. This is not just a share price issue: it affects staff morale (many of our staff were in shareholder schemes), leadership team motivation and our ability to do deals. Ultimately this is why I left a market, Aim, that had served LTG extremely well for a long period. So what would it take for London’s markets to be attractive to entrepreneurs? I can think of three tangible fixes. First, we simply must have a stable political backdrop to breed confidence and encourage consumer spend. Second, government incentives are crucial. We need policies to encourage investors to put their money back into the stock market and boost liquidity. Third, investors and entrepreneurs need to see a continued commitment to reducing the regulatory burden on companies and markets. The new listing rules governing London’s capital markets are a good start but what about removing tax relief on risk-free cash Isas to encourage investment in AIM stocks? Structural fixes can provide a better foundation but will not change much without good old-fashioned chutzpah from business leaders and fund managers. Imagine the British adopting an American-style positive attitude (without losing our authenticity and identity) and then delivering on our stated ambitious goals. I have spent my entire business life making bold statements that I hold myself accountable to. Of course, one occasionally fails but if the environment is supportive and you learn from mistakes then everyone wins eventually. Positive thinking is infectious, empowering and enjoyable — and astonishingly easy to do, if you are so inclined. So for now LTG is pursuing value-creation with the help of a US private equity firm but I really care about London’s markets rediscovering their role as a vibrant global financial market. This is crucial for the UK economy and should mean a lot to us all. -Jonathan Satchell is chief executive of Learning Technologies Group |
Posted at 28/2/2025 11:26 by gopher The share price has slipped back recently and is much the same as 12 months ago despite solid progress and an earnings enhancing acquisition.I wonder whether the management are doing enough to promote the,company with PIs and institutions, There are plenty of good value companies around at the moment, concentrating on running the business not quite enough. |
Posted at 26/2/2025 11:41 by simon gordon City Am - 26/2/25:Pets at Home shares surge as watchdog set to go easy on vets The animal care retailer’s share price has been under pressure recently due to a Competition and Markets Authority probe into the veterinary sector. Investors are concerned the body will impose stricter regulations on the sector. However, Jeffries analysts have suggested that changes are “likely to be largely limited to improved transparency and regulation”, and reported increased confidence price controls will not be implemented. The CMA’s probe, which prompted over 56,000 responses from the public and vet industry, has been looking into the UK’s vet industry following concerns pet owners are not getting value for money. This included concerns that owners were being overcharged for medicine, as well as fear that consolidation by larger practices may reduce competition in the market. The investigation is key for Pets at Home, as its growth has been driven by revenue in its veterinary arm recently, with like-for-like growth of 19.9 per cent in the 12 weeks to January 2. Retail revenue fell 2.8 per cent in the same period. The most recent published papers on the probe, released by the CMA on February 6, noted concerns that customers had a limited choice of services and said that the price of vet services has risen faster than inflation. However, Jefferies analysts noted that profit margins in the sector are “largely unchanged,” adding that the CMA is unlikely to implement broad pricing control measures. “Our expert is optimistic about the outlook for the sector, believing that the trading headwinds are ‘transientR Animal care is a large and growing market – in 2022, consumers in the UK spent nearly £10bn on pet-related products, up nearly 100 per cent in a decade. Pets at Home has more than 400 surgeries across the UK. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
